Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PCRX

Pacira BioSciences, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for PCRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.36

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-20 02:00 UTC.

What Pacira BioSciences, Inc. does

Pacira BioSciences is a Delaware-incorporated biopharmaceutical company with subsidiaries focused on developing non-opioid pain therapies. The company has three commercialized products: EXPAREL, a long-acting local anesthetic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for knee osteoarthritis; and iovera, a handheld cryoanalgesia device for drug-free pain control. The company is also advancing PCRX-201, a gene therapy in Phase 2 development for knee osteoarthritis, based on its proprietary high-capacity adenovirus vector platform.

Summarized from Pacira BioSciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.36
Return on equity1.01%
Debt/equity0.54

Revenue, margins & earnings

FY2021 Net income: $42MFY2021 Taxes & interest: $48MFY2021 Operating costs: $452M$542MFY2021FY2022 Net income: $16MFY2022 Taxes & interest: $44MFY2022 Operating costs: $607M$667MFY2022FY2023 Net income: $42MFY2023 Taxes & interest: $46MFY2023 Operating costs: $587M$675MFY2023FY2024: net loss $100M on revenue $701M$701MFY2024FY2025 Net income: $7MFY2025 Taxes & interest: $12MFY2025 Operating costs: $707M$726MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-09
  • 2026-10-09Senior Vice President, FinanceSale-6,000$217.9K
  • 2026-10-09Senior Vice President, FinanceOption exercise6,000$194.1K
  • 2026-10-09Senior Vice President, FinanceStock Option (Right to Buy)Option exercise-6,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Pacira BioSciences, Inc. do?

Pacira BioSciences is a Delaware-incorporated biopharmaceutical company with subsidiaries focused on developing non-opioid pain therapies.

When did PCRX last file with the SEC?

Pacira BioSciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:00 UTC. This page is also available as JSON at /api/data?ticker=PCRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PCRX and 5,000+ tickers.

Create a free account — keep PCRX
For your agent
GET /api/data?ticker=PCRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt